Breaking News

A PPARalpha agonist improves corticoid sparing and quality of life of children with atopic dermatitis

A PPARalpha agonist improves corticoid sparing and quality of life of children with atopic dermatitis

 
 

A randomized study which enrolled infants and young children (4-48 months) with atopic dermatitis assessed the effects of a new peroxisome proliferative-activated receptor alpha (PPARalpha) agonist emollient on topical corticosteroids sparing and quality of life for children and their families. Twenty-one days of treatment once or twice daily with dermo-corticosteroids (desonide 0.05%) alone or combined with the PPARalpha agonist, or once every other day with desonide plus the PPARalpha agonist, improved SCORAD (Severity Scoring of Atopic Dermatits) scores by > 60%. The best results were achieved in patients who received desonide plus the PPARalpha agonist (mean values of 73.7% vs. 60.5% with desonide alone). The combination of the two products was also ...

 
to Continue Reading, Login Now
 

Please Login

 
 
  
 
 
If you are a registered user but you have forgotten your password, please click here
 
If you are not a registered user, please register here

return to breaking news list